Trials in EGFR Mutated NSCLC: Flaura2 and Mariposa- 2024 Leading Developments in Lung Cancer
Drs. Desai and Abu Rous discuss trial data from Flaura2 and Mariposa as presented at 2024 ASCO, and the implications in treating EGFR+ NSCLC.
--------
10:53
Trials in ALK+ NSCLC: The Crown Study- 2024 Leading Developments in Lung Cancer
Drs. Desai and Abu Rous discuss the Crown study data as presented at ASCO 2024, and its implications in treating ALK+ NSCLC.
--------
3:47
Limited Stage Small Cell Lung Cancer: The Adriatic Study- 2024 Leading Developments in Lung Cancer
Drs. Desai and Abu Rous discuss the data, as presented at ASCO 2024, and how it may change the field of treatment for limited stage small Adriatic Studycell lung cancer.
--------
4:22
Trials in EGFR Mutated NSCLC: Mariposa2 and Laura- 2024 Leading Developments in Lung Cancer
Drs. Desai and Abu Rous discuss trial date from Mariposa2 and Laura as presented at 2024 ASCO, and the implications in treating EGFR+ NSCLC.
--------
6:26
Tarlatamab for Extensive Stage Small Cell Lung Cancer- 2024 Leading Developments in Lung Cancer
Drs. Desai and Abu Rous discuss using tarlatamab in treating extensive stage small cell lung cancer.
About GRACEcast - Discussions with the Global Resource for Advancing Cancer Education
In this podcast series, the Global Resource for Advancing Cancer Education (GRACE) works to bring professionals together with patients and caregivers to work in partnership. We interview patients, advocates and healthcare professionals to provide the most updated information for our community and to highlight important issues facing those dealing with a cancer diagnosis. For more information visit www.cancerGRACE.org. To join the conversation, visit https://cancergrace.org/forums
Listen to GRACEcast - Discussions with the Global Resource for Advancing Cancer Education, On Purpose with Jay Shetty and many other podcasts from around the world with the radio.net app
Canada - english